Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions
Por:
Lopez-Campos, F, Gajate, P, Romero-Laorden, N, Zafra-Martin, J, Juan-Otero M, Polo, SH, Moreno, AC and Counago, F
Publicada:
1 mar 2022
Resumen:
The advent of immunotherapy has revolutionized cancer treatment. Unfortunately, this has not been the case for metastatic castration-resistant prostate cancer (mCRPC), likely due to the heterogeneous and immune-suppressive microenvironment present in prostate cancer. The identification of molecular biomarkers that could predict response to immunotherapy represents one of the current challenges in this clinical scenario. The management of advanced castrationresistant prostate cancer is rapidly evolving and immunotherapy treatments, mostly consisting of immune checkpoint inhibitors combinations, BiTE (R) (bispecific T-cell engager) immune therapies, and chimeric antigen receptors (CAR) are in development with promising results. This review analyses the current evidence of immunotherapy treatments for mCRPC, evaluating past failures and promising approaches and discussing the directions for future research.
Filiaciones:
Lopez-Campos, F:
Hosp Univ Ramon y Cajal, Radiat Oncol Dept, Madrid 28024, Spain
Gajate, P:
Hosp Univ Ramon y Cajal, Med Oncol Dept, Madrid 28024, Spain
Romero-Laorden, N:
Hosp Univ La Princesa, Med Oncol Dept, Madrid 28006, Spain
Zafra-Martin, J:
Hosp Univ Virgen Victoria, Dept Radiat Oncol, Malaga 29010, Spain
Juan-Otero M:
CDB Hosp Clin, Serv Immunol, Plataforma Inmunoterapia HSJD Clin, Barcelona 08036, Spain
Polo, SH:
Hosp Univ Fdn Alcorcon, Med Oncol Dept, Alcorcon 28922, Spain
Moreno, AC:
Hosp Univ & Politecn La Fe, Radiat Oncol Dept, Valencia 46026, Spain
Counago, F:
Hosp Univ Quironsalud, Dept Radiat Oncol, Madrid 28223, Spain
Hosp La Luz, Dept Radiat Oncol, Madrid 28003, Spain
Univ Europea Madrid, Madrid 28670, Spain
Green Submitted, gold
|